Tuesday, October 10, 2017 9:41:45 AM
$PMCB will be filing an IND for a Phase 2b, pivotal trial, for solid pancreatic cancer tumor that have stopped responding to the gold standard treatment. PMCB has Orphan Drug Status on this indication. The master cell and working cell banks are being produced and tested. We are awaiting a shareholder update, which we may see this month.
This stock is highly speculative. Like any biotech company, the pipeline is subject to an imprecise timetable but moreso because we are dealing with what the FDA considers a biologic. It's actually approved by a separate division of the FDA from the one that approves new drugs. The good news is FDA's CBER has been approving and accelerating things faster than CDER has recently.
Anyway, on this Board you have an all out war between people who literally hate this company and those who would like to see it succeed. Pretty weird if you ask me. You can post a question about PMCB on just about any social media platform and you will get swarmed. Not sure why that is.
Personally, I'm a HOLD on $PMCB in the six month time frame.
Here's some of my recent DD. Take a look at my speculative post, "why would a large pharm..." to see the main reason I believe in PMCB's prospects.
$PMCB DD
Factual Posts:
Medical and scientific personnel currently associated with $PMCB
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134711479
Principal Investigator will be Dr. Hidalgo, MD, PhD
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134723048
Master Cell Bank being produced by Eurofins
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134794043
Austrianova's IP
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134787469
$PMCB's new corporate law firm
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134622365
$PMCB has four institutional investors with small, "placeholder" positions
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134474894
Recent $PMCB Events
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134528572
Speculative Posts:
Why would a large pharma company want anything to do with $PMCB?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134833898
Regarding the S-3 law firm
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134711413
Pattern related to S-3 Filings and partnerships
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134711743
Know What You Own. My posts should not be construed as investment advice.
Recent PMCB News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/21/2023 09:04:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/18/2023 10:04:06 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 09/15/2023 09:00:03 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/12/2023 01:56:25 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM